Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Axsome Therapeutics, Inc. - Common Stock
(NQ:
AXSM
)
174.76
-8.96 (-4.88%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axsome Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock
↗
Today 15:42 EST
TD Cowen analyst Joseph Thome’s new price target represents a potential upside of about 23% from AXSM’s current trading levels.
Via
Stocktwits
Topics
Artificial Intelligence
Axsome Therapeutics (AXSM): A CNS Powerhouse at a Commercial Crossroad
Today 10:23 EST
As of February 23, 2026, the biotechnology landscape has shifted away from the speculative fervor of the early 2020s toward a demand for commercial execution and sustainable revenue. Standing at the...
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q4 2025 Results, Meeting Revenue Forecasts but Posting Wider Loss
↗
Today 10:21 EST
Via
Chartmill
Axsome (AXSM) Q4 2025 Earnings Call Transcript
↗
Today 9:36 EST
Axsome (AXSM) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
AXSOME THERAPEUTICS INC (NASDAQ:AXSM) Fits the Minervini Growth Momentum Strategy
↗
January 12, 2026
Via
Chartmill
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Today 7:00 EST
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036
↗
February 22, 2026
The biotech is slowly rising in prominence.
Via
The Motley Fool
Topics
Intellectual Property
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
February 17, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Should You Buy Axsome Therapeutics Stock Before Feb. 23?
↗
February 05, 2026
The healthcare company is set to release its fourth-quarter results later this month.
Via
The Motley Fool
1 High-Flying Stock With More Upside Ahead
↗
February 03, 2026
Are we witnessing the birth of a biotech giant?
Via
The Motley Fool
Topics
Intellectual Property
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
January 27, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership
January 26, 2026
In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500....
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
AXSM Stock Rises After Analyst Hikes Price Target On Auvelity Drug Optimism
↗
January 16, 2026
Piper Sandler kept an ‘Overweight’ rating on Axsome Therapeutics’ shares, and raised the price target to $223 from $148.
Via
Stocktwits
Topics
Artificial Intelligence
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
January 15, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
January 12, 2026
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
↗
January 08, 2026
Via
MarketBeat
2 Healthcare Stocks to Buy for 2026 and Beyond
↗
January 08, 2026
These could be the next biotech giants.
Via
The Motley Fool
Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
January 01, 2026
As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric...
Via
MarketMinute
Here are the top movers in Wednesday's session.
↗
December 31, 2025
Via
Chartmill
Why Axsome Therapeutics Stock Rocketed Higher to End 2025
↗
December 31, 2025
Axsome Therapeutics shareholders got a New Year's gift from the FDA.
Via
The Motley Fool
The market is filled with gapping stocks in Wednesday's session.
↗
December 31, 2025
Via
Chartmill
Axsome Advances Toward FDA Filing For Drug To Treat Narcolepsy
↗
December 31, 2025
AXS-12 is being developed to treat cataplexy in narcolepsy by targeting norepinephrine and dopamine activity in the brain.
Via
Stocktwits
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
December 31, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
December 31, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
December 11, 2025
As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Emissions
2 Under-the-Radar Stocks to Buy Heading Into 2026
↗
December 01, 2025
These drugmakers are poised to profit from their innovative engines.
Via
The Motley Fool
Axsome (AXSM) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
Axsome (AXSM) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Axsome Therapeutics to Participate in Upcoming Investor Conferences
November 20, 2025
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Axsome Therapeutics, Inc. Common Stock - AXSM
November 10, 2025
From
Pomerantz LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.